Keros Therapeutics filed a Form 8-K to furnish an updated corporate presentation dated November 2026. The filing highlights the company's clinical-stage biopharmaceutical pipeline, specifically rinvatercept (KER-065) and elritercept (KER-050). Key updates include the commencement of a Phase 2 basket trial for rinvatercept in Duchenne muscular dystrophy (DMD), with initial data expected in the first half of 2027. The presentation also notes plans to engage regulators on an ALS trial design in late 2026 and details the global license agreement with Takeda Pharmaceuticals, which included a $200 million upfront payment for elritercept rights outside mainland China. Keros Therapeutics is a clinical-stage biopharmaceutical company developing product candidates targeting TGF-β superfamily signaling.
